PCN161 Systematic Review of Patient Reported Outcomes in Chronic Myeloid Leukemia  by Aggarwal, S. et al.
A420  VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  
tiveness analyses were compared with methods specified by NICE as the reference 
case in its 2004 and 2008 Methods Guides. The review focused on guidance published 
before June 2013 for medicines treating metastatic breast cancer, metastatic colorectal 
cancer, metastatic hormone-refractory prostate cancer and metastatic non-small-
cell lung cancer. Nineteen technology appraisals published between March 2002 and 
August 2012 met the inclusion criteria. Results: Common themes or variations that 
exist between utility values selected by manufacturers and independent academic 
groups for each metastatic cancer and between the 4 metastatic cancers were ana-
lysed. The research also explored the methodological issues that were considered by 
the Appraisal Committee relating to the selection of utility values. ConClusions: 
Therefore, this research provides insight to the methodological considerations regard-
ing incorporation of utility values that have informed health technology assessment 
decision-making in England for 4 metastatic cancers.
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PatieNts’ aNd Caregivers’ PrefereNCes for BoNe Metastases (BM) 
treatMeNts iN the UNited states
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objeCtives: Patients with BM from solid tumors often experience skeletal-related 
events [SREs]; commonly defined as pathologic fracture, radiation or surgery to 
bone, and spinal cord compression. Several bone-targeted agents are approved for 
the prevention of SREs. This study evaluated US patients’ and caregivers’ prefer-
ences in relation to available treatment options in the US. Methods: Adults with 
or adult caregivers of patients with a self-reported physician diagnosis of BM from 
a solid tumor completed a web-enabled discrete-choice experiment survey com-
prising a series of 10 choices between pairs of hypothetical medication profiles. 
Each profile included 6 medication attributes within a pre-defined range (primarily 
based on prescribing information and real-world practice): months until first SRE 
(10, 18 and 28 months); months until worsening of pain (3, 6, 10 months); annual 
risk of osteonecrosis of the jaw (ONJ; 0%, 1%, 5%); annual risk of renal impairment 
(0%, 4%, 10%); mode of administration (subcutaneous injection, 15-minute infusion, 
120-minute infusion); and monthly out-of-pocket cost to patients ($25, $75, $150, 
$330). Choice questions were based on an experimental design with known statisti-
cal properties. The survey was pretested with 15 patients and 11 caregivers using 
open-ended interviews. A separate main-effects random parameters logit model 
was estimated. Results: In total, 187 patients and 197 caregivers completed the 
survey. Among the attribute levels included, out-of-pocket cost to patients, risk of 
renal impairment, and months until first SRE were most important to both patients 
and caregivers. For those attributes, better outcomes were preferred to worse out-
comes (p< 0.05) except that risk of renal impairment between 4% and 10% was not 
significant for patients; costs between $25 and $75 were not significant for either 
group. ConClusions: When considering treatment choices for preventing skeletal 
complications associated with BM, patients and caregivers focused mainly on out-
of-pocket cost to patients, avoiding renal impairment, and delaying SREs.
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CliNiCal oUtCoMe assessMeNts iN fda oNCology laBels siNCe 2010
Meyers O.I.1, Foley K.2
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objeCtives: In 2009, the FDA released Final Guidance on Patient-Reported 
Outcomes (PROs) and has stated that standards for PROs apply equally to Clinician 
and Observer Reported Outcomes (ClinROs, ObsROs; collectively, clinical out-
come assessments - COAs). The objective was to survey labels for oncologic drugs 
approved in the three years since the “PRO Guidance” was finalized and to charac-
terize any COAs in these labels. Methods: CenterWatch maintains a list of FDA 
approved drugs following definitions established by the Tufts Center for the Study 
of Drug Development, including only drugs or NMEs newly approved by the FDA 
Center for Drug Evaluation and Research. From 2010 to the time of this review in 
2013, 45 oncologic drugs were approved by the FDA. The FDA approved product 
labels of each of these drugs was reviewed and each was tabulated according to its 
inclusion of COAs. Results: Few of the approved product labels reviewed included 
any reference to, much less data collected using PROs, ClinROs, or ObsROs. Several 
(e.g., carfilzomib) had clear statements to indicate that approval for the product was 
based on a predefined response rate rather than any “improvement in survival or 
symptoms.” The notable exceptions are fentanyl sublingual tablets and spray and 
abiraterone, with PRO data on pain. ConClusions: There are several explanations 
for the low rate of COAs in oncology labels, especially that oncology trials tend to be 
unblinded. The FDA has stated that open label designs cannot support PRO claims. 
Yet there is still a heavy reliance on outcomes such as progression free and overall 
survival. Three labels were identified with PRO data on pain, two of which were spe-
cifically indicated for pain rather than tumor control. This review suggests there are 
opportunities for sponsors and the FDA to increase the degree to which the patient’s 
voice is heard during the regulatory decision making process.
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systeMatiC review of PatieNt rePorted oUtCoMes iN ChroNiC 
Myeloid leUkeMia
Aggarwal S., Segal J., Topaloglu H.
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objeCtives: Patient reported outcomes (PRO) are becoming useful tools for collecting 
and generating evidence for new medical products to show improvements in health-
related quality of life (HRQoL). Chronic myeloid leukemia (CML) is now a chronic 
disease in which HRQoL is becoming important. The objective of this study was to 
review, analyze, and understand trends in the PRO instruments used in patients with 
CML. Methods: A systematic literature search for CML randomized controlled tri-
als (RCTs) with PROs endpoints was undertaken for the databases Pubmed, Embase, 
Biosis, Google Scholar, and Cochrane. Data was collected for the study size, interven-
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objeCtives: This study examined the responsiveness of preference-based meas-
ures based on the anchor of self-reported change in general health condition of 
patients with colorectal cancer (CRC). Methods: A baseline sample of 333 patients 
was recruited at the specialist outpatient clinic of academic teaching hospital in 
Hong Kong between September 2009 and July 2010, and was surveyed prospectively 
at 6-month follow-up. SF-6D preference-based indices were derived from the generic 
SF-6D measure (SF-6DDirect), from the Short Form-12 Health Survey (SF-6DSF-12) and 
also mapped from the condition-specific Functional Assessment of Cancer Therapy-
Colorectal (SF-6DFACT-C). The responsiveness of three measures was assessed using 
the internal responsiveness and external responsiveness. The 95% bias-corrected 
and accelerated bootstrapping confidence intervals were performed to compare the 
internal responsiveness statistics measured by standardized effect size, standard-
ized response mean, and responsiveness statistic. External responsiveness was 
evaluated by receiver operating characteristic (ROC) curve analysis that examined 
the ability to detect score changes with global health condition changes or dis-
criminate between the worsened and unchanged/improved groups. Results: 
Over half of patients reported no change in global health condition based on the 
self-reported anchor, whilst 15.1% and 32.9% of patients rated better and worse in 
current health condition compared to baseline respectively. In worsened group, 
internal responsiveness was satisfactory for the SF-6DDirect and SF-6DFACT-C prefer-
ence-based indices. The SF-6DSF-12 and SF-6DFACT-C indices were significantly more 
responsive to detect positive changes than the SF-6DDirect index in improved group. 
The SF-6DDirect and SF-6DFACT-C indices were more externally responsive based on 
ROC curve. The SF-6DFACT-C index was generally more responsive to changes in 
health status compared with other indices. ConClusions: Direct SF-6D measure 
was more responsive than mapped preference-based measures in improved group 
but the direction was reversed in worsened group. Use of a preference-based index 
mapped from a condition-specific measure captures both negative and positive 
important changes in HRQOL score among CRC.
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objeCtives: To elicit utility values from EQ-5D for patients with various stages of 
mCRC. Methods: An observational cross-sectional study consisting of one-time 
EQ-5D completion at enrollment was conducted in five hospitals in The Netherlands 
and the United Kingdom (UK). Patients were categorized into stable or progressed 
cohorts based on investigator assessment. Patients with mCRC were eligible if on 
second or subsequent lines of treatment or best supportive care [BSC], received 
prior oxaliplatin, no prior irinotecan, and had Eastern Cooperative Oncology Group 
(ECOG) performance status scores of 0-2 at second line initiation similar to the 
VELOUR trial. Chart data on patient demographics, clinical history, prior/current 
treatments, serious adverse events (SAEs) were collected. Average utilities were 
estimated; uni- and multivariate analyses were conducted. Results: A total of 
75 patients were enrolled, 42 patients stable on second line or third line follow-
ing an AE on second line and 33 progressed patients. Mean age was 63 (standard 
deviation [SD]= 10); 52% male. Most patients in the stable (98%) and progressed 
(88%) cohorts had ECOG scores of 0-1 at enrollment. 7% and 15% of patients in 
stable and progressed cohorts respectively had ongoing SAEs at enrollment. Mean 
utility scores were 0.741 (SD= 0.230) and 0.731 (SD= 0.292) for stable and progressed 
patients respectively. Higher proportions of patients reported increased anxiety/
depression (36% vs. 12%) and fewer problems with daily activities post-progression 
(64% vs. 38%). 83% and 42% of patients in stable and progressed cohorts respectively, 
were on treatment at enrollment. ConClusions: While the majority of the stable 
cohort had good performance status and few SAEs ongoing at enrollment, utility 
values were not much higher compared to the progressed cohort. Higher values in 
the progressed cohort may be attributed to exclusion of patients in palliative care 
centers, radiological versus symptomatic disease progression and patients remain-
ing on treatment, having few SAEs and good performance status at enrollment.
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exCelleNCe (NiCe) teChNology aPPraisals of MediCiNes for 4 
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objeCtives: National Institute for Health and Care Excellence (NICE) considers 
the quality-adjusted life year (QALY) to be the most appropriate generic measure of 
health benefit that reflects both mortality and health-related quality of life effects. 
The QALY is the sum of a person’s length of life in each health state multiplied by a 
quality-adjustment weight (that is, utility value) associated with that health state. 
Cost-effectiveness results are often sensitive to the choice of utility value, but relevant 
and comparable utility values are not always available leading to debate about the 
most appropriate utility values to include. The objective of the research was to review 
the health-related utility values used in economic models across NICE technology 
appraisal guidance for 4 metastatic cancers. Methods: A cross-sectional review of 
manufacturer submissions and reports produced by independent academic groups 
was carried out to identify the health-related utility values used. Information relating 
to the methods used to elicit utility values that were selected for use in cost-effec-
 VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  A421
total of 84 active ingredients had new indications or label changes. After removal of 
25 duplicate ingredients (or updated again during this timeframe), 59 labels and IFs 
were identified and reviewed. No product labels contained PRO information. However, 
in contrast 20 (34%) IFs contained PRO information. 10 of these IFs only stated that 
“QOL” or “PRO” was assessed without details on the questionnaires or results. The 
EORTC (European Organisation for Research and Treatment of Cancer) and FACT 
(Functional Assessment of Cancer Therapy) were explicitly stated as measures in 
four and three IFs, respectively. There were also three pain assessments; two Visual 
Analog Scale assessments and one utilizing the Brief Pain Inventory – Short Form 
(BPI-SF). ConClusions: Although no oncology labels contained PRO information, 
the IFs contained PRO information. 1/3 of product information contained a mention 
of PROs which can be used in discussions with clinicians.
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ChaNges iN PatieNt-rePorted oUtCoMes aMoNg PediatriC leUkeMia 
aNd lyMPhoMa PatieNts dUriNg the first 2-years Post allogeNeiC 
steM Cell traNsPlaNtatioN (allosCt)
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objeCtives: To explore changes in child-reported quality of life (QOL) of pediatric 
leukemia/lymphoma patients receiving alloSCT. Methods: Hierarchical linear 
modeling was used to explore trends in select PedsQL 4.0 sub-scales and individual 
items of 43 children ≥ 5 years of age. QOL was assessed once pre-alloSCT and on 
days 100, 180, 365, and 730, post-alloSCT. Results: Median age: 13.54 years, Range: 
4.66-23.12 years; leukemia: 76.7%; lymphoma: 23.3%; reduced-toxicity conditioning 
(RTC)/myeloablative conditioning (MAC): 44%/56%; chronic graft-versus-host disease 
(cGVHD): 27.9%. Emotional and social functioning was stable pre-to-post-alloSCT 
and comparable to a normative pediatric sample (p> .05), whereas physical func-
tioning was 19 points lower pre-alloSCT (M= 67.42; p< .01; ES= 1.26SD) with improved 
scores approaching norms by Day +730. 51-65% of children at baseline reported dif-
ficulties with sports/exercise, strength, pain, and fatigue. Significant improvements 
from baseline (M= 51.41) were observed in sports/exercise at a rate of 1.06 points-
per-month (ppm)/12.90 points-per-year (ppy) (t= 2.57; p= .01) and strength (M= 47.47; 
t= 2.05; p= .04) at a rate of 0.84 ppm (10.21ppy). Recipients of RTC significantly 
improved at a rate of 14.04ppy (slope= 1.16; t= 2.41; p= .02) compared to children who 
received MAC (-4.01ppy; slope= -0.33). Similarly gains in strength were significantly 
better for the RTC group (12.94ppy; slope= 1.06; t= 2.25; p= .02) than the MAC group 
(-10.62ppy; slope= -0.83). Levels of pain (M= 64.82; slope= 0.05ppm; t= 0.15; p= .88) and 
fatigue (M= 58.01; slope= 0.39ppm; t= 1.14; p= .26) remained unchanged irrespective 
of conditioning regimen. Emotional functioning of children ages 8-12 significantly 
improved from baseline (M= 70.18; slope= 1.78ppm; t= 2.89; p= .01), whereas children 
≥ 13 significantly declined post-alloSCT (M= 72.61; slope= -1.34ppm; t= -2.64; p= .01). 
Presence of cGVHD did not significantly affect outcomes scores. ConClusions: 
Improvements in exercise and strength were seen with RTC regimens whereas 
pain and fatigue remained unchanged independent of conditioning regimen. Older 
children may have more emotional difficulties post-alloSCT. These results highlight 
the importance of including QOL to monitor patients and further define outcomes 
for this population.
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objeCtives: To assess quality of life of Polish patients with a stoma using validated 
generic questionnaire. Methods: Adult patients with colostomy, ileostomy or uro-
stomy performed in Poland between July 2009 and December 2010 were included. 
Patients completed satisfaction survey at the discharge from the hospital, and The 
World Health Organization Quality of Life-BREF (WHOQOL-BREF) generic question-
naire at 3 months after surgery. Results: The study involved 1519 patients (71.5%, 
16.8%, 11.7% with colostomy, ileostomy and urostomy, respectively). The studied 
population was highly diversified in terms of: pain and discomfort, dependence on 
medical treatment and acceptance of physical appearance. 57% of patients with a 
stoma defined their quality of life as good or very good (mean 3.54 points; range: 
1 to 5; SD 0.73). The subjects were characterized by low quality of life assessment 
in the physical health and psychological domains (53.5 and 60.0 pts.) and by high 
evaluation in the environment and social relationships domains (69.6 and 70.2 pts.). 
Respondents highly assessed: the level of social support, home environment, physi-
cal environment, personal relationships. Low assessment was related to: sexual 
activity, ability to work, dependence on medical treatment, financial resources, 
satisfaction with health. ConClusions: This is the first Polish study on the quality 
of life of patients with a stoma, based on validated generic questionnaire. The results 
should help improve standards of care for patients with a stoma.
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objeCtives: To assess the impact of anxiety and depression measured by Hospital 
Anxiety and Depression Scale (HADS) on 1-year HRQoL measured by EuroQol-3L (EQ-
5D) and EORTC-QLQ-C30 on patients with colorectal cancer.This aspect of continuity 
tions, year, PRO instrument, and results for PROs. Analysis was conducted to identify 
trends in commonly used PRO instruments and results were categorized as posi-
tive, neutral, or negative. Results: Eight RCTs with a total of 3,342 patients were 
identified. In these studies, there were eight different PROs instruments identified: 
FACT-Leu, SF-36, FSI, PSQI, MSAS-SF, FACT-BRM, EQ-5D, and MDASI-CML. The most 
commonly used instruments were FACT-Leu (used in 1,336 patients) and FACT-BRM 
(used in 1,199 patients). Five studies reported positive results with improvement in 
quality of life (QoL) symptoms versus comparator treatments. Two studies reported 
results highlighting significant deterioration in QoL versus patients with no cancer. 
One study reported QoL in various types of CML and showed significant deterioration 
in patients with chronic phase CML versus those with acute and blast phase CML. 
Studies also identified two QoL domains, depression and fatigue, which matter most 
for patients with CML. ConClusions: Patients with CML have significant deterio-
ration in their QoL. PRO instruments such as FACT-Leu and FACT-BRM can aid in 
generating evidence to show which therapies improve patient QoL.
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PatieNt rePorted oUtCoMes iN MetastatiC CastratioN-resistaNt 
Prostate CaNCer
Aggarwal S., Segal J., Kumar S.
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objeCtives: Patient reported outcomes (PRO) are becoming useful tools for col-
lecting and generating evidence for new medical products to show improvements 
in health-related quality of life (HRQoL). Castration-Resistant Prostate Cancer 
(CRPC) is a chronic disease with high importance for patient HRQoL. The objective 
of this study was to review, analyze, and understand trends in the PRO instruments 
used in patients with CRPC. Methods: A systematic literature search for CRPC 
randomized controlled trials (RCTs) with PROs endpoints was undertaken for the 
databases Pubmed, Embase, Biosis, Google Scholar, and Cochrane. Data was col-
lected for the study size, interventions, year, PRO instrument, and results for PROs. 
Analysis was conducted to identify trends in commonly used PRO instruments 
and categorize results as positive, neutral or negative. Results: Ten RCTs with 
a total of 5,797 patients were identified. In these studies there were thirteen dif-
ferent PROs instruments were identified that were FACT-P, FACT-G, BPI-SF, EQC30, 
EQPR25, FLIC, SDS, SUF, PDA, IPDA, PROSQOLI, SF-36, and QOLM-P14. The most 
commonly used instrument were FACT-P (used in 4,297 patients) and EQC-30 (used 
in 1,091 patients). Six studies reported positive results with improvement in qual-
ity of life symptoms (QoL) versus comparator treatments. Fours studies reported 
results with deterioration in (QOL). Three studies reported improvement in pain 
scores. ConClusions: Patients with CRPC have relatively longer survival and 
hence QoL is an important consideration for these patients. PRO instruments such 
as FACT-P and EQC-30 have been commonly used to generate evidence to show 
which therapies improve patient QoL.
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are “dizzy” aNd “lightheaded” the saMe CoNCePt or seParate 
CoNCePts? ChalleNges iN CoNCePtUal eQUivaleNCe of these terMs iN 
20 laNgUages
Eremenco S.1, Arnold B.J.2
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objeCtives: Feeling “dizzy” or “lightheaded” are common concepts in patient-reported 
outcome (PRO) instruments in a number of conditions. The Functional Assessment of 
Cancer Therapy – Anemia (FACT-An) subscale contains an item assessing “feeling dizzy 
(lightheaded)” as one concept while other instruments propose to assess the symptoms 
as two separate concepts or items. The purpose of this study was to translate and assess 
conceptual equivalence of this concept across 20 languages (21 countries). Methods: 
The FACT-An was translated following the FACIT Translation methodology which is 
consistent with ISPOR guidelines for translation and cultural adaptation of PRO 
measures (Wild et al., 2005). The translation process for each language consisted of: 2 
forward translations by native translators, reconciliation of the forward translations, 
1 back-translation by an English-speaker fluent in the target language, 3 reviews by 
native translators or clinicians, final reconciliation by a native speaking linguist, and 
harmonization. Interviews were conducted among 456 native-speaking patients in 21 
countries. Data were analyzed to assess linguistic and cultural validity of the FACT-An in 
each language and confirm conceptual equivalence. Results: Mean age of the sample 
(N= 456) was 55 years, (range 19-88) and 58% were male. During the translation phase, 12 
of the 20 languages translated the concept of dizzy (lightheaded) using only one term, 
and the remaining 8 languages provided two terms. The rationale was that one word 
was used to describe this set of symptoms and it would be a complicated explanation 
to address the second term. The translations were well understood and considered rel-
evant. ConClusions: The majority of languages in this study provided only one term 
for the concept of dizzy (lightheaded) indicating that it may be problematic to assess 
the concept as two separate symptoms in future questionnaires in other languages 
where this concept is not separated as it is in English.
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Pro ClaiMs iN JaPaNese oNCology ProdUCt laBeliNg
Crawford B.
Adelphi Values, Tokyo, Japan
objeCtives: There is a growing use of patient-reported outcomes (PRO) in the US 
and Europe but little is known about Asia. Oncology in particular is an area of growing 
interest. This study sought to review PRO labeling within oncology products over the 
last five years in Japan. Methods: Oncology labels were identified by reviewing the 
Pharmaceutical and Medical Devices Agency (PMDA) postings of label changes for 
the past 5 years (2007-2012). For identified products with label changes, labels and 
Interview Forms (IF) were acquired and reviewed. The IF is used as a supplement to 
the label in Japan to provide additional data that will not fit within the package insert. 
Only PROs used for potential promotion were evaluated. Symptoms such as pain listed 
in the adverse events or safety sections were not included in this review. Results: A 
